ziftomenib (KO-539) / University of Michigan, Kura Oncology 
Welcome,         Profile    Billing    Logout  

10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ziftomenib (KO-539) / Kura Oncology
2019-001545-41: First in human clinical trial of the study drug KO-539 in patients with leukemia

Not yet recruiting
1/2
236
Europe
ziftomenib, KO-539, Capsule, hard
Kura Oncology, Inc., KURA ONCOLOGY INC, Kura Oncology, Inc.
Relapsed and/or refractory Acute Myeloid Leukemia, Relapsed and/or refractory leukemia, Diseases [C] - Cancer [C04]
 
 
KOMET-001, NCT04067336: First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
199
Europe, Canada, US
Ziftomenib
Kura Oncology, Inc.
Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia
09/24
09/25
NCT05848687: TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Recruiting
1/2
90
US
Dexamethasone, Mitoxantrone, PEG asparaginase, Bortezomib, Vorinostat, Mercaptopurine, Methotrexate, Blinatumomab, Ziftomenib
Tanja Andrea Gruber, Pediatric Oncology Experimental Therapeutics Investigators' Consortium, Amgen, Lucile Packard Foundation for Children's Health, Kura Oncology, Inc.
Lymphoblastic Leukemia
12/28
12/33
NCT06376162: Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

Not yet recruiting
1
20
NA
Ziftomenib, Cytarabine, Fludarabine
LLS PedAL Initiative, LLC, Kura Oncology
Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia, Relapsed/Refractory NPM1-m Acute Leukemia
08/27
08/27
NCT06440135: Ziftomenib Maintenance Post Allo-HCT

Not yet recruiting
1
22
US
Ziftomenib, KO-539
Massachusetts General Hospital
Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, NPM1 Mutation, KMT2A Rearrangement
09/26
09/27
NCT06397027: A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

Not yet recruiting
1
22
US
Ziftomenib, Venetoclax, ABT-199, GDC-0199, Azacitidine, 5-azacytidine,, 5-aza, Vidaza™, 5-AZC, AZA-CR, Ladakamycin, Azacytidine, NSC-102816
M.D. Anderson Cancer Center, Kura Oncology, Inc.
Refractory Acute Leukemia, Pediatric Relapsed
12/28
12/30
NCT06448013: A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

Not yet recruiting
1
22
US
Venetoclax, ABT-199, GDC-0199, Gemtuzumab, Gemtuzumab ozogamicin, Mylotarg, Ziftomenib
M.D. Anderson Cancer Center, Kura Oncology, Inc.
Acute Myeloid Leukemia
12/28
12/30
KOMET-007, NCT05735184: A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML

Recruiting
1
212
US
Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine
Kura Oncology, Inc.
Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype Acute Leukemia, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma
05/26
05/27
NCT06001788: Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1
171
US
Ziftomenib, KO-539, Fludarabine, Idarubicin, Cytarabine, Gilteritinib, Xospata, Granulocyte colony-stimulating factor
Kura Oncology, Inc.
AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
08/26
08/27
NCT05738538: Expanded Access to Ziftomenib

Available
N/A
NA
ziftomenib
Kura Oncology, Inc.
Acute Lymphoblastic Leukemia, With Appropriate Mutations, Acute Myeloid Leukemia, With NPM1 Mutations
 
 

Download Options